• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EVOLVE 短程 DAPT 研究的主要结果：生物可吸收聚合物涂层依维莫司洗脱支架治疗高出血风险患者的 3 个月双联抗血小板治疗评估。

Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent.

机构信息

Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York (A.J.K.).

Baylor Scott & White Heart and Vascular Hospital, Dallas, TX (R.S., J.W.C.).

出版信息

Circ Cardiovasc Interv. 2021 Mar;14(3):e010144. doi: 10.1161/CIRCINTERVENTIONS.120.010144. Epub 2021 Mar 1.

DOI:10.1161/CIRCINTERVENTIONS.120.010144
PMID:33641374
Abstract

[Figure: see text].

摘要

[图：见正文]。

相似文献

1
Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent.EVOLVE 短程 DAPT 研究的主要结果：生物可吸收聚合物涂层依维莫司洗脱支架治疗高出血风险患者的 3 个月双联抗血小板治疗评估。
Circ Cardiovasc Interv. 2021 Mar;14(3):e010144. doi: 10.1161/CIRCINTERVENTIONS.120.010144. Epub 2021 Mar 1.
2
First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).首例人体生物可吸收聚合物涂层依维莫司洗脱支架的评估：DESOLVE I 试验（载有依维莫司和生物可吸收聚合物的 DES 治疗原发性冠状动脉病变患者）的影像学和临床结果。
JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.
3
Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry.经生物可降解聚合物药物洗脱支架置入术后采用极短疗程双联抗血小板治疗患者的临床结局：前瞻性多中心 REIWA 注册研究的原理和设计。
Cardiovasc Interv Ther. 2020 Oct;35(4):398-404. doi: 10.1007/s12928-020-00694-y. Epub 2020 Aug 10.
4
One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients.高出血风险患者生物可吸收聚合物依维莫司洗脱支架术后 1 个月双联抗血小板治疗。
J Am Heart Assoc. 2022 Mar 15;11(6):e023454. doi: 10.1161/JAHA.121.023454. Epub 2022 Feb 3.
5
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.生物可吸收聚合物药物洗脱支架置入 6 个月与 18 个月后双联抗血小板治疗。
JACC Cardiovasc Interv. 2017 Jun 26;10(12):1189-1198. doi: 10.1016/j.jcin.2017.04.019.
6
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.评估高出血风险行经皮冠状动脉介入治疗患者 3 个月双联抗血小板治疗的 EVOLVE 短程 DAPT 研究的原理和设计。
Am Heart J. 2018 Nov;205:110-117. doi: 10.1016/j.ahj.2018.08.004. Epub 2018 Aug 17.
7
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.依维莫司洗脱支架术后延长双联抗血小板治疗的获益与风险
JACC Cardiovasc Interv. 2016 Jan 25;9(2):138-47. doi: 10.1016/j.jcin.2015.10.001.
8
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.长期依维莫司洗脱支架置入后 6 个月与 12 个月双联抗血小板治疗：血管内超声-XPL 随机临床试验。
JACC Cardiovasc Interv. 2016 Jul 25;9(14):1438-46. doi: 10.1016/j.jcin.2016.04.036. Epub 2016 May 17.
9
Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex Percutaneous Coronary Intervention With Early Discontinuation of Dual-Antiplatelet Therapy.生物可吸收聚合物依维莫司洗脱协同支架在早期停用双联抗血小板治疗的高危患者复杂经皮冠状动脉介入治疗中的初步经验
J Invasive Cardiol. 2017 Feb;29(2):36-41. Epub 2016 Dec 15.
10
Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.新型生物可吸收聚合物涂层依维莫司洗脱冠状动脉支架的疗效与安全性：EVOLVE II随机试验
Circ Cardiovasc Interv. 2015 Apr;8(4). doi: 10.1161/CIRCINTERVENTIONS.114.002372.

引用本文的文献

1
Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review.在有活动性出血或即将进行手术的患者中管理抗凝和双联抗血小板治疗：一项范围综述。
J Brown Hosp Med. 2023 Jun 22;2(3):81037. doi: 10.56305/001c.81037. eCollection 2023.
2
Left Main Disease and Bifurcation Percutaneous Coronary Intervention: Focus on Antithrombotic Therapy.左主干病变与分叉病变经皮冠状动脉介入治疗：聚焦抗栓治疗
US Cardiol. 2021 Jun 14;15:e11. doi: 10.15420/usc.2020.34. eCollection 2021.
3
Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology.
是否一种方案适合所有人？介入心脏病学中个性化抗血小板治疗的理由。
Future Cardiol. 2024;20(9):499-515. doi: 10.1080/14796678.2024.2384217. Epub 2024 Aug 2.
4
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope.接受经皮冠状动脉介入治疗的高出血风险患者的抗血小板治疗：如履薄冰。
Rev Cardiovasc Med. 2022 Jun 1;23(6):207. doi: 10.31083/j.rcm2306207. eCollection 2022 Jun.
5
Imaging in Percutaneous Coronary Intervention.经皮冠状动脉介入治疗中的影像学
Rev Cardiovasc Med. 2022 May 31;23(6):204. doi: 10.31083/j.rcm2306204. eCollection 2022 Jun.
6
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.非ST段抬高型急性冠状动脉综合征患者接受经皮冠状动脉介入治疗时，高出血风险患者的1个月与3个月双重抗血小板治疗对比研究
EuroIntervention. 2024 May 20;20(10):e630-e642. doi: 10.4244/EIJ-D-23-00658.
7
Importance of Short-Term Neointimal Coverage of Drug-Eluting Stents in the Duration of Dual Antiplatelet Therapy.药物洗脱支架短期新生内膜覆盖在双联抗血小板治疗持续时间中的重要性。
J Clin Med. 2024 Mar 17;13(6):1730. doi: 10.3390/jcm13061730.
8
Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis.基于文献计量分析视角的冠状动脉疾病药物洗脱支架研究
Front Cardiovasc Med. 2024 Feb 19;11:1288659. doi: 10.3389/fcvm.2024.1288659. eCollection 2024.
9
Surface Engineering of Bioactive Coatings for Improved Stent Hemocompatibility: A Comprehensive Review.用于改善支架血液相容性的生物活性涂层的表面工程：综述
Materials (Basel). 2023 Oct 29;16(21):6940. doi: 10.3390/ma16216940.
10
Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents.冠状动脉支架平台的演变：当前使用的药物洗脱支架简要概述。
J Clin Med. 2023 Oct 24;12(21):6711. doi: 10.3390/jcm12216711.